APA (7th ed.) Citation

Masri, A., Lester, S. J., Stendahl, J., Hegde, S. M., Sehnert, A., Balaratnam, G., . . . Wang, A. (2023). LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY. Journal of the American College of Cardiology (JACC), 81, 346. https://doi.org/10.1016/S0735-1097(23)00790-8

Chicago Style (17th ed.) Citation

Masri, Ahmad, Steven J. Lester, John Stendahl, Sheila M. Hegde, Amy Sehnert, Ganesh Balaratnam, Shawna Fox, and Andrew Wang. "LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY." Journal of the American College of Cardiology (JACC) 81 (2023): 346. https://doi.org/10.1016/S0735-1097(23)00790-8.

MLA (9th ed.) Citation

Masri, Ahmad, et al. "LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY." Journal of the American College of Cardiology (JACC), vol. 81, 2023, p. 346, https://doi.org/10.1016/S0735-1097(23)00790-8.